References
Barbui C, Guaiana G, Garattini S (2001) Regulatory issues in Europe. J Clin Psychopharmacol 21:545–548
Garattini S, Bertelé V (2001) Adjusting Europe's drug regulation to public health needs. Lancet 358:64–67
Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371–1376
Kerwin RW (1994) The new atypical antipsychotics: a lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry 164:141–148
Weiss E, Hummer M, Koller D, Ulmer H, Fleischhacker WW (2000) Off-label use of antipsychotic drugs. J Clin Psychopharmacol 20:695–698
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Barbui, C., Tansella, M. & Garattini, S. Varying and "atypical" indications for atypical antipsychotics. Psychopharmacology 169, 205–206 (2003). https://doi.org/10.1007/s00213-003-1495-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1495-x